- The trend backdrop is active with a 11-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
VIYASH
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Viyash Scientific Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
277.0 INR
9.9%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 21.3% above the Trend Line and sits at 83.9% of its 52-week range. The latest completed week returned 9.9%, after a -0.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 50/100.
Setup score
65
out of 100
Latest Close
277.0 INR
7 Aug 2026
1W Return
9.9%
latest completed week
4W Return
-0.3%
short-term follow-through
12W Return
23.4%
quarterly tape
Trend Breadth
80.8%
42 of 52 weeks active
Volume Ratio
1.4x
vs 13-week average
- 4 reversal markers appear in the recent smart-money tape.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
9.9%
Latest completed week; four-week move -0.3%.
Indicator stack
82/52
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
50/100
25 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 21.3% above the Trend Line and sits at 83.9% of its 52-week range. The latest completed week returned 9.9%, after a -0.3% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.4x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.8612-week average 0.68
12-week confirmation
Trend active11/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.86Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers44 reversal markers
No recent accumulation markers. 4 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -0.3% over four weeks, 23.4% over 12 weeks, and 64.8% over one year. The current trend has remained active for 11 consecutive weeks.
Performance by holding period
Active trend streak11 weeks
Active weeks in one year42
Trend breadth80.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.43Latest activity-pressure read.
Pressure change-67.3%Four-week change in activity pressure.
Leadership27.96Latest relative-leadership reading.
RS change-19.3%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength54/100Blend of value, momentum, and quality. Underlying universe rank 47; rank 1 is best.
Value18/100Relative valuation strength. Underlying universe rank 83; rank 1 is best.
Quality77/100Profitability and accounting quality. Underlying universe rank 24; rank 1 is best.
Momentum94/100Medium-term price momentum. Underlying universe rank 7; rank 1 is best.
Growth89/100Revenue and earnings growth. Underlying universe rank 12; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework23/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 101.1x Price divided by trailing earnings.
- Price / sales
- 4.6x Market value relative to trailing revenue.
- EV / EBITDA
- 27.3x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 1.5% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 52.7% Gross profit retained from each unit of revenue.
- Operating margin
- 12.1% Operating profit retained from revenue.
- Free-cash-flow margin
- 7.1% Free cash flow generated from revenue.
- Return on invested capital
- 7.6% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 13.3% Latest one-year revenue growth.
- EPS growth
- 337.2% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -20.5% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 8/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -1.4% Net share repurchases relative to market value.
- Shareholder yield
- -1.4% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.5x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 25 relevant articles.
0 positive · 24 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-7.0%Distance below the 52-week high.
13-week volatility5.6%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+9.9%Week of 7 Aug.
Worst week-6.6%Week of 24 Jul.
Latest week+9.9%Week of 7 Aug.
Shape of recent returns
Strong gains8
Modest gains5
Flat weeks0
Modest losses9
Sharp losses4
Recent vol5.6%13-week weekly-return volatility.
Base vol5.2%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew5.2% / -3.3%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank53 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank42 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape65/100
Trend, activity pressure, participation, and risk combine to a 65/100 tape read.
Indicator analysis79/100Latest 12-week confirmation: trend 11/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.86; 4 reversal markers Factors59/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 85; Small Cap Core rank 91 SVQF23/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1215.5 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 25 relevant articles.
Viyash Scientific Q1 Results: Earnings call scheduled for Aug 12 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 277.0 INR | 9.9% | 228.3 INR | 169.8 INR | 0.43 | 27.96 | 11.0M | On |
| 31 Jul 2026 | 252.0 INR | 0.4% | 225.7 INR | 168.6 INR | 0.64 | 18.43 | 5.3M | On |
| 24 Jul 2026 | 250.9 INR | -6.6% | 224.3 INR | 167.6 INR | 1.00 | 21.91 | 6.5M | On |
| 17 Jul 2026 | 268.6 INR | -3.3% | 223.1 INR | 166.6 INR | 1.25 | 28.51 | 5.2M | On |
| 10 Jul 2026 | 277.8 INR | -5.6% | 221.1 INR | 165.4 INR | 1.31 | 34.64 | 8.6M | On |
| 3 Jul 2026 | 294.1 INR | 9.2% | 218.9 INR | 164.2 INR | 1.21 | 43.53 | 1.6M | On |
| 26 Jun 2026 | 269.3 INR | 5.6% | 215.7 INR | 162.9 INR | 1.14 | 34.02 | 0 | On |
| 19 Jun 2026 | 254.9 INR | 2.0% | 214.2 INR | 161.8 INR | 1.30 | 28.22 | 2.5M | On |
| 12 Jun 2026 | 249.9 INR | -2.1% | 213.7 INR | 160.7 INR | 1.47 | 28.73 | 2.4M | On |
| 5 Jun 2026 | 255.2 INR | -2.6% | 213.0 INR | 159.6 INR | 1.52 | 33.72 | 2.9M | On |
| 29 May 2026 | 261.9 INR | 6.5% | 211.6 INR | 158.4 INR | 1.50 | 37.27 | 17.0M | On |
| 22 May 2026 | 246.1 INR | 9.6% | 210.0 INR | 157.2 INR | 0.93 | 29.05 | 31.7M | Off |
| 15 May 2026 | 224.5 INR | 2.2% | 208.6 INR | 156.1 INR | 0.50 | 19.03 | 5.7M | Off |
| 8 May 2026 | 219.6 INR | 7.8% | 207.8 INR | 155.2 INR | 0.13 | 14.46 | 7.2M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.